How to Evaluate a DSP for Pharmaceutical Advertising
A requirements-to-evidence process for choosing a demand-side platform for pharma, covering health data, controls, supply, measurement, and fees.
The short answer
Choosing a demand-side platform for pharmaceutical advertising is a multi-year decision that affects which audiences you can reach, which supply you can buy, how you measure outcomes, and how much of each dollar reaches working media. Many teams choose based on demos and relationships. A more reliable approach starts from written requirements and asks for evidence against each one.
This anchor page introduces the DSP and supply series. For a comparison of named platforms, see the DSP comparison for pharma and the DSP picker tool.
The evaluation process
- Write requirements from the brand's use cases before seeing demos. See DSP requirements before demos.
- Classify each requirement as must-have, important, or nice-to-have.
- Request evidence, not claims, for each must-have.
- Run scripted demos that test specific scenarios. See DSP demo questions.
- Pilot with a controlled budget and compare against a baseline.
- Score and decide with a documented rationale.
Six areas to evaluate
| Area | Key questions |
|---|---|
| Health audiences | Which HCP and DTC data integrations exist? How is NPI targeting verified? |
| Controls | Can you control frequency, placements, exclusions, and sensitive categories reliably? |
| Supply | What inventory is available? How transparent are supply paths? See supply path optimization. |
| Measurement | Which outcome partners integrate? Is log-level data available? |
| Fees | What is the full fee stack? See DSP fee transparency. |
| Service | Who supports the account? What is the escalation path? |
Evidence over claims
For each must-have requirement, ask for evidence you can verify:
- Documentation of how a feature works and its limitations.
- Live demonstration in the platform, not slides.
- Sample reports, including log-level data samples.
- References from comparable pharma advertisers, asked specific questions.
- Pilot results on your own campaigns.
A DSP that cannot show a feature working live should be scored as if it does not have it.
Healthcare-specific considerations
Pharma buyers need controls that general advertisers may not: sensitive category exclusions, HCP list verification, support for required safety information in formats, and privacy-reviewed data flows. Check whether the platform has healthcare-specific policies and how they affect what you can do. Review platform documentation against your own compliance requirements; do not rely on the vendor's summary.
Avoid common mistakes
- Deciding on features you will not use. Focus on your actual use cases.
- Ignoring switching costs. Moving DSPs involves retraining, new integrations, and a learning period.
- Treating the demo as proof. Demos show best cases. Pilots show reality.
- Skipping the fee reconciliation. A lower platform fee can be offset by higher data or tech fees.
Practical takeaway
Before any DSP demo, write down your top ten requirements and what evidence would prove each one. Share the list with vendors in advance and score them against it afterward.
Sources
- Media Rating Council, Standards and Guidelines
- IAB Tech Lab, sellers.json
- ANA, Programmatic Media Supply Chain Transparency Study
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
Everything in this series
This guide is the entry point. Each article below answers one narrower decision in depth.
How to Write DSP Requirements Before Watching Demos
Define pharma DSP requirements for audience, identity, supply, controls, measurement, workflow, data access, privacy, and commercials before demos.
3 min read →DSPs & Supply QualityQuestions to Ask in a Healthcare DSP Demo
Scenario-based questions for healthcare DSP demos that require live evidence in the platform instead of slides, covering targeting, controls, supply, and reporting.
3 min read →DSPs & Supply QualitySupply Path Optimization for Pharma: What to Remove and Why
A removal rule for pharma supply path optimization that balances transparency, uniqueness, performance, cost, and resilience instead of cutting paths blindly.
3 min read →DSPs & Supply QualityHow to Evaluate Pharma PMPs Before Committing Budget
A deal evidence card and pre and post-launch validation checklist for private marketplace deals in pharma programmatic.
3 min read →DSPs & Supply QualityDSP Fee Transparency: A Pharma Buyer's Reconciliation Guide
How to reconcile DSP invoices to log-level data with a cost waterfall that separates media, platform, data, verification, and unexplained differences.
3 min read →DSPs & Supply QualityWhat Log-Level Data Should a Pharma Advertiser Request?
Minimum log-level data field sets by use case for pharma programmatic, plus a review of fields you should not collect for privacy reasons.
3 min read →DSPs & Supply QualityHow to Use ads.txt, sellers.json, and SupplyChain Objects Together
A worked trace showing what ads.txt, sellers.json, and the SupplyChain object each prove about a programmatic impression, and what they cannot prove.
3 min read →DSPs & Supply QualityInventory Quality vs. Audience Quality in Pharma Media
A two-axis diagnostic that keeps inventory quality and audience quality separate, so one strong dimension does not hide a weak one in pharma media.
3 min read →DSPs & Supply QualityHow to Diagnose a Sudden Change in Programmatic Inventory Mix
A change-point checklist for sudden shifts in pharma programmatic domain, app, or deal mix, tied to likely causes and the evidence that confirms each.
3 min read →New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.